Drugs / DF5112
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07232121 | Jan → Dec 2026 expected | — | Dragonfly Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Dragonfly Therapeutics | Results Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule dragonflytx.com ↗
This milestone follows the successful completion of the intravenous (IV) dosing phase which demonstrated DF5112's strong depletion of both Th17 and B cells. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-19 | Dragonfly Therapeutics | Dragonfly Therapeutics Announces Encouraging Early Results from the Phase 1 for DF5112, its CCR6-Targeting Molecule dragonflytx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF5112 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07232121 ↗ |
| Route | Intravenous | “DF5112 administered IV or SC” NCT07232121 ↗ |
| Route | Subcutaneous | “DF5112 administered IV or SC” NCT07232121 ↗ |